Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Impact of beta-amyloid-specific florbetaben PET imaging on confidence in early diagnosis of Alzheimer's disease.

Schipke CG, Peters O, Heuser I, Grimmer T, Sabbagh MN, Sabri O, Hock C, Kunz M, Kuhlmann J, Reininger C, Blankenburg M.

Dement Geriatr Cogn Disord. 2012;33(6):416-22. doi: 10.1159/000339367. Epub 2012 Jul 20. Erratum in: Dement Geriatr Cogn Disord. 2012;34(3-4):262.

2.

Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls.

Barthel H, Luthardt J, Becker G, Patt M, Hammerstein E, Hartwig K, Eggers B, Sattler B, Schildan A, Hesse S, Meyer PM, Wolf H, Zimmermann T, Reischl J, Rohde B, Gertz HJ, Reininger C, Sabri O.

Eur J Nucl Med Mol Imaging. 2011 Sep;38(9):1702-14. doi: 10.1007/s00259-011-1821-1. Epub 2011 May 6.

PMID:
21547601
3.

Florbetaben to trace amyloid-β in the Alzheimer brain by means of PET.

Barthel H, Sabri O.

J Alzheimers Dis. 2011;26 Suppl 3:117-21. doi: 10.3233/JAD-2011-0068. Review.

PMID:
21971456
4.

Impact of partial volume effect correction on cerebral β-amyloid imaging in APP-Swe mice using [(18)F]-florbetaben PET.

Brendel M, Delker A, Rötzer C, Böning G, Carlsen J, Cyran C, Mille E, Gildehaus FJ, Cumming P, Baumann K, Steiner H, Haass C, Herms J, Bartenstein P, Rominger A.

Neuroimage. 2014 Jan 1;84:843-53. doi: 10.1016/j.neuroimage.2013.09.017. Epub 2013 Sep 20.

PMID:
24055703
5.

Influence of scan duration on the accuracy of β-amyloid PET with florbetaben in patients with Alzheimer's disease and healthy volunteers.

Tiepolt S, Barthel H, Butzke D, Hesse S, Patt M, Gertz HJ, Reininger C, Sabri O.

Eur J Nucl Med Mol Imaging. 2013 Jan;40(2):238-44. doi: 10.1007/s00259-012-2268-8. Epub 2012 Oct 27.

PMID:
23104671
6.

PET quantification of 18F-florbetaben binding to β-amyloid deposits in human brains.

Becker GA, Ichise M, Barthel H, Luthardt J, Patt M, Seese A, Schultze-Mosgau M, Rohde B, Gertz HJ, Reininger C, Sabri O.

J Nucl Med. 2013 May;54(5):723-31. doi: 10.2967/jnumed.112.107185. Epub 2013 Mar 7.

7.

Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer's disease.

Villemagne VL, Mulligan RS, Pejoska S, Ong K, Jones G, O'Keefe G, Chan JG, Young K, Tochon-Danguy H, Masters CL, Rowe CC.

Eur J Nucl Med Mol Imaging. 2012 Jun;39(6):983-9. doi: 10.1007/s00259-012-2088-x. Epub 2012 Mar 8.

PMID:
22398958
8.

Positron emission tomography radiopharmaceuticals for imaging brain Beta-amyloid.

Vallabhajosula S.

Semin Nucl Med. 2011 Jul;41(4):283-99. doi: 10.1053/j.semnuclmed.2011.02.005. Review.

PMID:
21624562
9.

Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism.

Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O'Keefe G, Tochon-Danguy H, Chan G, Berlangieri SU, Jones G, Dickinson-Rowe KL, Kung HP, Zhang W, Kung MP, Skovronsky D, Dyrks T, Holl G, Krause S, Friebe M, Lehman L, Lindemann S, Dinkelborg LM, Masters CL, Villemagne VL.

Lancet Neurol. 2008 Feb;7(2):129-35. doi: 10.1016/S1474-4422(08)70001-2. Epub 2008 Jan 10.

PMID:
18191617
10.

Longitudinal assessment of cerebral β-amyloid deposition in mice overexpressing Swedish mutant β-amyloid precursor protein using 18F-florbetaben PET.

Rominger A, Brendel M, Burgold S, Keppler K, Baumann K, Xiong G, Mille E, Gildehaus FJ, Carlsen J, Schlichtiger J, Niedermoser S, Wängler B, Cumming P, Steiner H, Herms J, Haass C, Bartenstein P.

J Nucl Med. 2013 Jul;54(7):1127-34. doi: 10.2967/jnumed.112.114660. Epub 2013 May 31.

11.

Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study.

Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K, Hiemeyer F, Wittemer-Rump SM, Seibyl J, Reininger C, Sabri O; Florbetaben Study Group.

Lancet Neurol. 2011 May;10(5):424-35. doi: 10.1016/S1474-4422(11)70077-1. Epub 2011 Apr 8.

PMID:
21481640
12.

Partial-Volume Effect Correction Improves Quantitative Analysis of 18F-Florbetaben β-Amyloid PET Scans.

Rullmann M, Dukart J, Hoffmann KT, Luthardt J, Tiepolt S, Patt M, Gertz HJ, Schroeter ML, Seibyl J, Schulz-Schaeffer WJ, Sabri O, Barthel H.

J Nucl Med. 2016 Feb;57(2):198-203. doi: 10.2967/jnumed.115.161893. Epub 2015 Nov 5.

PMID:
26541776
13.

In vitro characterization of [18F]-florbetaben, an Aβ imaging radiotracer.

Fodero-Tavoletti MT, Brockschnieder D, Villemagne VL, Martin L, Connor AR, Thiele A, Berndt M, McLean CA, Krause S, Rowe CC, Masters CL, Dinkelborg L, Dyrks T, Cappai R.

Nucl Med Biol. 2012 Oct;39(7):1042-8. doi: 10.1016/j.nucmedbio.2012.03.001. Epub 2012 Apr 11.

PMID:
22503458
14.

Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias.

Villemagne VL, Ong K, Mulligan RS, Holl G, Pejoska S, Jones G, O'Keefe G, Ackerman U, Tochon-Danguy H, Chan JG, Reininger CB, Fels L, Putz B, Rohde B, Masters CL, Rowe CC.

J Nucl Med. 2011 Aug;52(8):1210-7. doi: 10.2967/jnumed.111.089730. Epub 2011 Jul 15.

15.

Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.

Villain N, Chételat G, Grassiot B, Bourgeat P, Jones G, Ellis KA, Ames D, Martins RN, Eustache F, Salvado O, Masters CL, Rowe CC, Villemagne VL; AIBL Research Group.

Brain. 2012 Jul;135(Pt 7):2126-39. doi: 10.1093/brain/aws125. Epub 2012 May 23.

17.

Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study.

Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, Ouchi Y, Senda K, Murayama S, Ishii K, Takao M, Beach TG, Rowe CC, Leverenz JB, Ghetti B, Ironside JW, Catafau AM, Stephens AW, Mueller A, Koglin N, Hoffmann A, Roth K, Reininger C, Schulz-Schaeffer WJ; Florbetaben Phase 3 Study Group.

Alzheimers Dement. 2015 Aug;11(8):964-74. doi: 10.1016/j.jalz.2015.02.004. Epub 2015 Mar 28.

18.

Aβ imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study.

Ong KT, Villemagne VL, Bahar-Fuchs A, Lamb F, Langdon N, Catafau AM, Stephens AW, Seibyl J, Dinkelborg LM, Reininger CB, Putz B, Rohde B, Masters CL, Rowe CC.

J Neurol Neurosurg Psychiatry. 2015 Apr;86(4):431-6. doi: 10.1136/jnnp-2014-308094. Epub 2014 Jun 26.

PMID:
24970906
19.

Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline.

Grundman M, Pontecorvo MJ, Salloway SP, Doraiswamy PM, Fleisher AS, Sadowsky CH, Nair AK, Siderowf A, Lu M, Arora AK, Agbulos A, Flitter ML, Krautkramer MJ, Sarsour K, Skovronsky DM, Mintun MA; 45-A17 Study Group.

Alzheimer Dis Assoc Disord. 2013 Jan-Mar;27(1):4-15. doi: 10.1097/WAD.0b013e318279d02a.

PMID:
23203162
20.

Positron emission tomography with Pittsburgh compound B in diagnosis of early stage Alzheimer's disease.

Jia J, Sun B, Guo Z, Zhang J, Tian J, Tang H, Wang L.

Cell Biochem Biophys. 2011 Jan;59(1):57-62. doi: 10.1007/s12013-010-9111-2.

PMID:
20714824
Items per page

Supplemental Content

Write to the Help Desk